Changing perspectives of the role of chemotherapy in advanced prostate cancer.
The use of cytotoxic chemotherapy in advanced prostate adenocarcinoma has been validated by the recent demonstration of survival benefit in two large randomized phase III trials. Before publication of these landmark trials, SWOG 9916 and TAX 327, no chemotherapeutic regimen had shown survival benefit in the treatment of androgen independent prostate cancer (AIPC). These trials provide new encouragement for the use of chemotherapy in all stages of disease. Improved communication between medical and urologic oncologists and early patient referral for clinical trial participation remains essential for identifying new chemotherapeutic regimens with improved activity in AIPC and for defining the role of chemotherapy in earlier-stage disease. This article discusses the role of chemotherapy as the current standard of care for the treatment of AIPC and provides a historical perspective of the trials that preceded the development of current docetaxel-based regimens.
Burgess
Earle F
EF
Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232-6307, USA.
Roth
Bruce J
BJ
D000728:Androgens; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D000077143:Docetaxel; D004961:Estramustine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000209:etiology; D043823:Taxoids / Q000627:therapeutic use
D000728:Androgens; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine; D008942:Mitoxantrone